In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.
Some quinolone antibiotics cause increases in levels of theophylline in plasma that lead to serious adverse effects. We investigated the mechanism of this interaction by developing an in vitro system of human liver microsomes. Theophylline (1,3-dimethylxanthine) was incubated with human liver microsomes in the presence of enoxacin, ciprofloxacin, norfloxacin, or ofloxacin. Theophylline, its demethylated metabolites (3-methylxanthine and 1-methylxanthine), and its hydroxylated metabolite (1,3-dimethyluric acid) were measured by high-pressure liquid chromatography, and Km and Vmax values were estimated. Enoxacin and ciprofloxacin selectively blocked the two N demethylations; they significantly inhibited the hydroxylation only at high concentrations. Norfloxacin and ofloxacin caused little or no inhibition of the three metabolites at comparable concentrations. The extent of inhibition was reproducible in five different human livers. Inhibition enzyme kinetics revealed that enoxacin caused competitive and mixed competitive types of inhibition. The oxo metabolite of enoxacin caused little inhibition of theophylline metabolism and was much less potent than the parent compound. Nonspecific inhibition of cytochrome P-450 was ruled out since erythromycin N demethylation (cytochrome P-450 mediated) was unaffected in the presence of enoxacin. These in vitro data correlate with the clinical interaction described for these quinolones and theophylline. We conclude that some quinolones are potent and selective inhibitors of specific isozymes of human cytochrome P-450 that are responsible for theophylline metabolism. This in vitro system may be useful as a model to screen similar compounds for early identification of potential drug interactions.
Sarkar
M
M
School of Pharmacy, West Virginia University, Morgantown 26506.
Polk
R E
RE
Guzelian
P S
PS
Hunt
C
C
Karnes
H T
HT
D001711:Biotransformation / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D002939:Ciprofloxacin / Q000494:pharmacology*; D004347:Drug Interactions; D015365:Enoxacin / Q000494:pharmacology*; D006801:Humans; D006900:Hydroxylation; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism*; D009643:Norfloxacin / Q000494:pharmacology*; D013806:Theophylline / Q000378:metabolism* / Q000493:pharmacokinetics; D014527:Uric Acid / Q000031:analogs & derivatives / Q000032:analysis; D014970:Xanthines / Q000032:analysis
D014970:Xanthines; D014527:Uric Acid; D015365:Enoxacin; D002939:Ciprofloxacin; C053085:1-methylxanthine; D013806:Theophylline; C031274:1,3-dimethyluric acid; D009643:Norfloxacin; C029703:3-methylxanthine